

ENDO HEALTH SOLUTIONS INC.
Form 4
March 03, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
HYATT MICHAEL

2. Issuer Name and Ticker or Trading Symbol
ENDO HEALTH SOLUTIONS INC.
[ENDP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
745 FIFTH AVENUE

(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
02/28/2014

Director 10% Owner
 Officer (give title below) Other (specify below)

NEW YORK, NY 10151

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value, \$.01 per share ⁽¹⁾	02/28/2014		D		234,228	D	(1) 0
Common Stock, par value, \$.01 per share ⁽²⁾	02/28/2014		D		25,000	D	(2) 0 I In Trust
2010 Stock Incentive Plan Restricted	02/28/2014		D		6,515	D	(3) 0 D

Stock Units
(RSU) ⁽³⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
2000 Stock Incentive Plan Stock Options (NQ) ⁽⁴⁾	\$ 20.42	02/28/2014		D	10,000	⁽⁴⁾ 03/12/2014	Common Stock	10,000
2004 Stock Incentive Plan Stock Options (NQ) ⁽⁵⁾	\$ 22.06	02/28/2014		D	10,000	⁽⁵⁾ 03/11/2015	Common Stock	10,000
2004 Stock Incentive Plan Stock Options (NQ) ⁽⁶⁾	\$ 31.43	02/28/2014		D	10,000	⁽⁶⁾ 03/13/2016	Common Stock	10,000
2000 Stock Incentive Plan Stock	\$ 29.84	02/28/2014		D	4,567	⁽⁷⁾ 03/12/2017	Common Stock	4,567

Options (NQ) ⁽⁷⁾									
2007 Stock Incentive Plan	\$ 24.63	02/28/2014	D	6,764	⁽⁸⁾	03/12/2018	Common Stock	6,764	
Options (NQ) ⁽⁸⁾									
2007 Stock Incentive Plan	\$ 16.8	02/28/2014	D	10,384	⁽⁹⁾	03/12/2019	Common Stock	10,384	
Options (NQ) ⁽⁹⁾									
2007 Stock Incentive Plan	\$ 23.82	02/28/2014	D	8,094	⁽¹⁰⁾	03/12/2020	Common Stock	8,094	
Options (NQ) ⁽¹⁰⁾									

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HYATT MICHAEL 745 FIFTH AVENUE NEW YORK, NY 10151	X			

Signatures

/s/ Caroline B. Manogue, by power of attorney 03/03/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On February 28, 2014, Endo Health Solutions, Inc. ("Endo") and Paladin Laboratories Inc. ("Paladin") consummated a transaction under an arrangement agreement pursuant to which each of Endo and Paladin was acquired by a new Irish holding company, Endo International plc ("New Endo"). Under the terms of the arrangement agreement (a) New Endo acquired Paladin pursuant to a plan of arrangement under Canadian law and (b) a newly formed subsidiary of New Endo merged with and into Endo, with Endo as the surviving corporation in the merger (the "Merger") and an indirect wholly owned subsidiary of New Endo. At the effective time of the Merger, each Endo common share was cancelled and converted into the right to receive one New Endo ordinary share. The number here represents shares of Endo disposed of pursuant to the Merger, of which 223,853 are owned directly and 10,375 are held in trusts for which Mr. Hyatt serves as trustee and holds either sole or shared power of disposition and power to vote

Edgar Filing: ENDO HEALTH SOLUTIONS INC. - Form 4

- (2) These indirectly owned common shares, representing shares of common stock held in trusts, were also disposed of pursuant to the Merger and each was converted into the right to receive one New Endo ordinary share.
- These restricted stock units granted on March 12, 2013 under the 2010 Stock Incentive Plan, which vest 100% on March 12, 2014, were assumed by New Endo in the Merger and converted into New Endo restricted stock units with the same terms and conditions as the original Endo restricted stock units.
- (3) These non-qualified stock options granted on March 12, 2004 under the 2000 Stock Incentive Plan, which are fully vested as of February 28, 2014, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.
- (4) These non-qualified stock options granted on March 11, 2005 under the 2004 Stock Incentive Plan, which are fully vested as of February 28, 2014, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.
- (5) These non-qualified stock options granted on March 13, 2006 under the 2004 Stock Incentive Plan, which are fully vested as of February 28, 2014, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.
- (6) These non-qualified stock options granted on March 12, 2007 under the 2000 Stock Incentive Plan, which are fully vested as of February 28, 2014, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.
- (7) These non-qualified stock options granted on March 12, 2008 under the 2007 Stock Incentive Plan, which are fully vested as of February 28, 2014, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.
- (8) These non-qualified stock options granted on March 12, 2009 under the 2007 Stock Incentive Plan, which are fully vested as of February 28, 2014, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.
- (9) These non-qualified stock options granted on March 12, 2010 under the 2007 Stock Incentive Plan, of which 6,071 are vested as of February 28, 2014 with the unvested portion generally vesting 25% per year on each remaining grant date anniversary through March 12, 2014, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.
- (10)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.